Progress reported with candidate dengue vaccine

Trials in Thailand with a candidate vaccine for dengue, a potentially fatal mosquito-borne disease, have shown it to protect against three of the four virus strains, its French maker said Wednesday.

The first trials in humans proved the vaccine was safe and represented a key milestone in the quest for a dengue jab, vaccine-maker Sanofi Pasteur executive vice president Michel De Wilde said in a statement.

"This is also an important development for global public health, since there is currently no specific treatment or prevention for dengue."

The says the disease infects between 50 million and 100 million people every year and kills more than 20,000 -- mainly in tropical and of Asia and , but expanding rapidly including to parts of Europe.

Researchers estimate that some three billion people live in regions susceptible to dengue contagion and another 20 million tourists pass through them.

The disease caused by one of four virus serotypes results in fever, aches, rashes, vomiting and in rare cases death. Children are especially vulnerable.

Sanofi Pasteur said its was effective against three of the four virus serotypes and analyses were under way "to understand the lack of protection for the fourth".

The company conducted trials on 4,000 children aged four to 11 in Thailand's Muang district, the results of which have yet to be published in a peer-reviewed medical journal.

Larger Phase III trials with 31,000 adults and children are taking place in 10 countries in Asia and Latin America.

add to favorites email to friend print save as pdf

Related Stories

Dengue vaccine could be ready by 2015: Sanofi

Jun 10, 2011

French drugs group Sanofi said Friday that its vaccine against dengue, a mosquito-borne infection that kills thousands of people around the world each year, could be launched in about four years.

Thailand developing dengue vaccine: researcher

Feb 22, 2011

Researchers in Thailand say they have developed a prototype vaccine against dengue fever and will conduct further tests with the aim of bringing it to market within a decade.

Human clinical trial of NIH-developed dengue vaccine begins

Aug 09, 2010

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at ...

Human antibody for dengue virus isolated

Jun 22, 2012

(Phys.org) -- A group of scientists in Singapore and the UK have isolated a human antibody capable of effectively neutralizing the mosquito-borne dengue virus. Dengue fever is currently incurable and infects ...

Recommended for you

Seniors successfully withdraw from meds

12 hours ago

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

Flu vaccine for expectant moms a top priority

Sep 18, 2014

Only about half of all pregnant women in the U.S. get a flu shot each season, leaving thousands of moms-to-be and their babies at increased risk of serious illness.

Experts want restrictions on testosterone drug use (Update)

Sep 17, 2014

Federal health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans ...

User comments